A peptide-duocarmycin conjugate targeting the Thomsen-Friedenreich antigen has potent and selective antitumour activity

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)
7 Downloads (Pure)


Solid phase synthesis allowed the rapid generation of a peptide-drug conjugate. A peptide targeting the Thomsen-Friedenreich antigen (TFα) was conjugated to the alkylating subunit of the potent cytotoxin duocarmycin SA. The compound, containing a cathepsin B cleavable linker, was shown to be active and selective against TFα expressing tumour cell lines.

Original languageEnglish
Pages (from-to)1745–1749
Number of pages5
JournalBioconjugate Chemistry
Issue number7
Early online date9 Jun 2020
Publication statusPublished - 15 Jul 2020

Cite this